CSOI, melatonin, sleep quality
Conditions
Interventions
Data collection will occur through administration of an electronic, retrospective, self-administered questionnaire. Comprising seven parts, the questionnaire assesses demographics, melatonin therapy s
Sponsors
Faculty of Veterinary Medicine, Pharmacy Department, Utrecht University. In samenwerking met Gelderse Vallei Hospital Ede.
Eligibility
Inclusion criteria
Inclusion criteria: All participants from the MELDOS trial (ISRCTN20033346)
Exclusion criteria
Exclusion criteria: N/A
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current melatonin therapy status ((dis)continuation of therapy, dose, compliance, drug holidays, rebound sleep disturbance after (temporary) cessation of therapy, reason(s) for cessation or resuming of therapy) and current sleep habits (PSQI and ISI score). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are chronotype (MEQ score, MSFsc), caffeine consumption, smoking status, use of electronics before bedtime and pubertal development. Furthermore, possible side effects and adverse events will be evaluated. | — |
Contacts
Public ContactI.M. van Geijlswijk
Yalelaan 106
Outcome results
None listed